SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.
Covid-19
SARS-CoV-2
click chemistry
epitope mapping
peptide microarrays
serological test
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
11 Jan 2021
11 Jan 2021
Historique:
received:
11
12
2020
revised:
06
01
2021
accepted:
06
01
2021
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
A workflow for rapid SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 spike (S), nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples highlighted an epitope of the N protein (region 155-71) providing good diagnostic performance in discriminating Covid-19 positive vs. healthy individuals. Using this epitope, 92% sensitivity and 100% specificity were reached for IgG detection in Covid-19 samples, and no cross-reactivity with common cold coronaviruses was detected. Likewise, IgM immunoreactivity in samples collected within the first month after symptoms onset showed discrimination ability. Overall, epitope 155-171 from N protein represents a promising candidate for further development and rapid implementation in serological tests.
Identifiants
pubmed: 33440622
pii: vaccines9010035
doi: 10.3390/vaccines9010035
pmc: PMC7827214
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Regione Lombardia
ID : 229472
Organisme : European Commission
ID : 874735
Références
EBioMedicine. 2020 Aug;58:102911
pubmed: 32711254
Talanta. 2019 Dec 1;205:120152
pubmed: 31450458
Analyst. 2019 Sep 9;144(18):5353-5367
pubmed: 31384857
Cell Res. 2020 Aug;30(8):702-704
pubmed: 32612199
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Anal Chem. 2009 Jul 1;81(13):5197-203
pubmed: 19485342
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249
pubmed: 33372199
Cell Mol Immunol. 2020 Oct;17(10):1095-1097
pubmed: 32895485
Mol Cell Proteomics. 2015 Jul;14(7):1871-84
pubmed: 25922409
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Antibodies (Basel). 2019 Mar 12;8(1):
pubmed: 31544829
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
ACS Cent Sci. 2020 May 27;6(5):591-605
pubmed: 32382657
Bioconjug Chem. 2016 Nov 16;27(11):2669-2677
pubmed: 27731634
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
ACS Infect Dis. 2018 Jun 8;4(6):998-1006
pubmed: 29570266
PLoS One. 2020 Sep 9;15(9):e0238089
pubmed: 32903266
Lancet. 2020 May 23;395(10237):1595-1598
pubmed: 32380041
J Infect Dis. 2005 Jun 15;191(12):2033-7
pubmed: 15897988
Anal Chim Acta. 2017 Aug 29;983:189-197
pubmed: 28811026